Myriad Genetics
MYGN
221 hedge funds and large institutions have $2.23B invested in Myriad Genetics in 2019 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 71 increasing their positions, 79 reducing their positions, and 45 closing their positions.
4% more capital invested
Capital invested by funds: $2.14B → $2.23B (+$88.1M)
0.29% more ownership
Funds ownership: 105.01% → 105.3% (+0.29%)
6% less funds holding
Funds holding: 235 → 221 (-14)
10% less repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 79
16% less call options, than puts
Call options by funds: $11.7M | Put options by funds: $13.8M
29% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 45
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Glenview Capital Management
New York
|
+$107M |
| 2 |
EARNEST Partners
Atlanta,
Georgia
|
+$98.7M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$29.1M |
| 4 |
New York State Common Retirement Fund
Albany,
New York
|
+$23.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$47.7M |
| 2 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$35.6M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$24.6M |
| 4 |
D.E. Shaw & Co
New York
|
-$23.9M |
| 5 |
State Street
Boston,
Massachusetts
|
-$16M |
MYGN Hedge Fund Activity: Q3 2019 in Review
221 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q3 2019, worth a combined $2.23B — up 4.1% from $2.14B a quarter earlier.
Sellers outnumbered buyers: 45 funds closed out of MYGN and 32 opened new positions — a net loss of 13 holders — while 79 trimmed existing stakes and 71 added.
The largest buyer was Glenview Capital Management, opening a new position worth an estimated $107M. The largest seller was Millennium Management, exiting entirely with an estimated $47.7M sold.
- 221 institutional investors held Myriad Genetics (MYGN) as of Q3 2019, down from 235 in Q2 2019.
- Funds reported $2.23B of Myriad Genetics stock for Q3 2019, up 4.1% quarter-over-quarter.
- 32 funds opened new Myriad Genetics positions in Q3 2019 and 45 closed out, a net change of -13 holders.
- The largest Myriad Genetics buyer in Q3 2019 was Glenview Capital Management, an estimated $107M added.
- The largest Myriad Genetics seller in Q3 2019 was Millennium Management, an estimated $47.7M sold.
Based on aggregated 13F filings for Q3 2019.